/CANF
CANF Stock - Can-Fite BioPharma Ltd.
Healthcare|BiotechnologyAMEX
$0.22+10.00%
+$0.02 (+10.00%) • Jan 2
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1945.5%upside
Target: $4.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CANF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.22 – $0.22
TARGET (TP)$4.50
STOP LOSS$0.20
RISK/REWARD1:214.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.04
52W High$46.60
52W Low$0.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $674,000 | $743,000 | $810,000 | $853,000 | $763,000 |
| Gross Profit | $674,000 | $743,000 | $810,000 | $853,000 | $763,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-8,130,000 | $-8,195,000 | $-10,096,000 | $-12,842,000 | $-14,139,000 |
| Net Income | $-7,880,000 | $-7,634,000 | $-10,173,000 | $-12,595,000 | $-14,443,000 |
| Net Margin | -1169.1% | -1027.5% | -1255.9% | -1476.6% | -1892.9% |
| EPS | $-21.60 | $-36.00 | $-75.00 | $-180.00 | $-253.80 |
Company Overview
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CANFBeat Rate
47%
Last 15 quarters
Avg Surprise
-121.3%
EPS vs Estimate
Beats / Misses
7/7
1 met exactly
Latest EPS
$-4.29
Q3 2025
EPS Surprise History
Q3 23
+25.9%
$-0.40vs$-0.54
Q4 23
0.0%
$-0.43vs$-0.43
Q1 24
-14.8%
$-0.31vs$-0.27
Q2 24
-62.5%
$-0.65vs$-0.40
Q3 24
-11.1%
$-0.40vs$-0.36
Q1 25
-59.3%
$-0.43vs$-0.27
Q2 25
-1686.4%
$-4.29vs$-0.24
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 13, 2026 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | — | $-4.29 | — | — |
Q2 2025 | Apr 14, 2025 | $-0.24 | $-4.29 | -1686.4% | ✗ MISS |
Q1 2025 | Jan 2, 2025 | $-0.27 | $-0.43 | -59.3% | ✗ MISS |
Q3 2024 | Sep 19, 2024 | $-0.36 | $-0.40 | -11.1% | ✗ MISS |
Q2 2024 | Jun 20, 2024 | $-0.40 | $-0.65 | -62.5% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.27 | $-0.31 | -14.8% | ✗ MISS |
Q4 2023 | Nov 30, 2023 | $-0.43 | $-0.43 | 0.0% | = MET |
Q3 2023 | Aug 31, 2023 | $-0.54 | $-0.40 | +25.9% | ✓ BEAT |
Q2 2023 | Jun 1, 2023 | $-1.52 | $-0.65 | +57.2% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-21.73 | — | — |
Q4 2022 | Nov 25, 2022 | $-1.00 | $-0.90 | +10.0% | ✓ BEAT |
Q3 2022 | Aug 25, 2022 | $-0.90 | $-0.80 | +11.1% | ✓ BEAT |
Q2 2022 | May 26, 2022 | $-1.20 | $-0.90 | +25.0% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-37.18 | — | — |
Q4 2021 | Nov 26, 2021 | $-1.00 | $-1.90 | -90.0% | ✗ MISS |
Q3 2021 | Aug 26, 2021 | $-1.20 | $-1.90 | -58.3% | ✗ MISS |
Q2 2021 | May 27, 2021 | $-1.70 | $-1.20 | +29.4% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | — | $-47.02 | — | — |
Q4 2020 | Nov 30, 2020 | $-2.50 | $-2.40 | +4.0% | ✓ BEAT |
Latest News
Can-Fite Biopharma shares are trading higher after the company announced that the Brazilian Patent Office granted it Patent No. BR112015002697-4, entitled "Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.
📈 PositiveBenzinga•Dec 26, 2025, 01:47 PM
Can-Fite Granted Brazilian Patent BR112015002697-4 For Use Of A3 Adenosine Receptor Agonist In Treatment Of Sexual Dysfunction
📈 PositiveBenzinga•Dec 26, 2025, 12:01 PM
Can-Fite Biopharma shares are trading lower after the company announced a 1-for-3,000 reverse share split.
📉 NegativeBenzinga•Dec 24, 2025, 01:58 PM
Can-Fite Biopharma shares are trading lower after the company announced a 1-for-3,000 reverse share split.
📉 NegativeBenzinga•Dec 23, 2025, 09:55 PM
Can-Fite BioPharma approves 1-for-3,000 reverse share split; shares down
📉 NegativeSeeking Alpha•Dec 23, 2025, 09:52 PM
Can-Fite BioPharma Announces 1-For-3,000 Reverse Share Split, Effective January 5, 2026
📉 NegativeBenzinga•Dec 23, 2025, 09:49 PM
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4
➖ NeutralBenzinga•Dec 17, 2025, 12:42 PM
Can-Fite BioPharma shares are trading higher after the company announced an update on its clinical development activities and financial status.
📈 PositiveBenzinga•Dec 16, 2025, 05:17 PM
Can-Fite BioPharma Advances Multiple Phase II/III Trials For Namodenoson And Piclidenoson; Reports $13.65M Cash Position
📈 PositiveBenzinga•Dec 16, 2025, 02:19 PM
Can Fite BioPharma Ltd To Present Latest Developments In Advanced Stage Drug Pipeline At Noble Capital Markets 21st Annual Emerging Growth Equity Conference On December 3 2025
📈 PositiveBenzinga•Nov 26, 2025, 12:07 PM
Shares of Can-Fite Biopharma are trading higher. The company announced that it aims to advance second veterinary partnership focused on its Phase III anti-cancer drug candidate, Namodenoson, at BioFIT 2025.
📈 PositiveBenzinga•Nov 24, 2025, 07:32 PM
Can-Fite Aims To Advance Second Veterinary Partnership Focused On Namodenoson, Phase III Anti-Cancer Drug Candidat, At BioFIT 2025
📈 PositiveBenzinga•Nov 24, 2025, 12:05 PM
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target
📈 PositiveBenzinga•Nov 18, 2025, 07:30 PM
Can-Fite Biopharma shares are trading higher after the company announced that a patient treated with Namodenoson has reached an overall survival of 9 years to date with complete response to treatment.
📈 PositiveBenzinga•Nov 18, 2025, 02:02 PM
Can-Fite Reports 9-Year Complete Cure In Advanced Liver Cancer Patient Treated With Namodenoson As Pivotal Phase III HCC Study Enrolls In Israel Europe And US
📈 PositiveBenzinga•Nov 18, 2025, 12:06 PM
Can-Fite BioPharma Announces Patients Treated With Namodenoson Reaches Overall Survival Of 9 Years With Complete Response
📈 PositiveBenzinga•Nov 18, 2025, 12:05 PM
HC Wainwright & Co. Assumes Can Fite Biofarma at Buy, Announces Price Target of $2.5
📈 PositiveBenzinga•Nov 4, 2025, 11:39 AM
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target
📈 PositiveBenzinga•Sep 16, 2025, 11:03 AM
Can-Fite Highlights Potential Of Namodenoson As Patient Shows Resolution Of Life-Threatening Esophageal Varices In Advanced Liver Disease
📈 PositiveBenzinga•Sep 15, 2025, 11:06 AM
Frequently Asked Questions about CANF
What is CANF's current stock price?
Can-Fite BioPharma Ltd. (CANF) is currently trading at $0.22 per share. The stock has moved +10.00% today.
What is the analyst price target for CANF?
The average analyst price target for CANF is $4.50, based on 1 analyst.
What sector is Can-Fite BioPharma Ltd. in?
Can-Fite BioPharma Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is CANF's market cap?
Can-Fite BioPharma Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CANF pay dividends?
No, Can-Fite BioPharma Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDRX
Biodexa Pharmaceuticals Plc
$2.35
Mkt Cap: $0.0B
CLDI
Calidi Biotherapeutics, Inc.
$1.09
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.21
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.23
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$0.72
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$6.15
Mkt Cap: $0.0B
OGEN
Oragenics, Inc.
$0.86
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.40
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.37
Mkt Cap: $0.0B
Explore stocks similar to CANF for comparison